---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-281247"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:53:24.262805+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cytek Q3 revenue $40.5M (+18% YoY); net income $1.6M; guides FY near high end of $160-168M

## Summary
- Revenue $40.5M (+18% YoY); gross margin improved to 66.4% from 61.9%.
- Net income $1.6M (vs $1.4M); adjusted EBITDA $7.3M (vs $5.5M).
- FY2022 revenue guidance reaffirmed closer to high end of $160M-$168M range.
- Appointed Chris Williams as Chief Operating Officer during the quarter.

## SEC filing metadata
- accession: 0001193125-22-281247
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312522281247/0001193125-22-281247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312522281247/d384960d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-281247
- JSON: https://secwatch.observer/filing/0001193125-22-281247.json
- Plain text: https://secwatch.observer/filing/0001193125-22-281247.txt

## Key facts
- Earnings Releases
  Cytek Biosciences, Inc. reported the third quarter ended September 30, 2022 results: revenue $40.5 million, net income $1.6 million. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $40.5 million
  - Net income: $1.6 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenue was $40.5 million for the third quarter, representing an 18% increase over the corresponding quarter of 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312522281247/0001193125-22-281247-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.